2002
DOI: 10.1522/17563967
|View full text |Cite
|
Sign up to set email alerts
|

Effets des intermétalliques de fer et des porosités sur les propriétés de traction et d impact sur les alliages de coulée Al-Si-Cu et Al-Si-Mg

Abstract: Aluminum-silicon (Al-Si) alloys are an important class of materials that constitute the majority of aluminum cast parts produced, due to their superior properties and excellent casting characteristics. Within this family of alloys, Al-Si-Cu and Al-Si-Mg cast alloys are frequently employed in automotive applications. The commercially popular 319 and 356 alloys, representing these two alloy systems, were selected for study in the present work, with the aim of investigating the effect of iron intermetallics and p… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2014
2014
2016
2016

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 37 publications
(56 reference statements)
0
2
0
Order By: Relevance
“…Several ongoing trials are combining endocrine therapy with selective inhibitors of the PI3K/Akt/mTOR/D-cyclin-CDK4/6 pathways in the neoadjuvant setting, such as letrozole with or without the PI3K inhibitor taselisib (LORELEI) and letrozole with or without the CDK4/6 inhibitor palbociclib (PALLET) . Preliminary analysis of a phase 2 trial examining palbociclib combined with anastrozole as neoadjuvant therapy for stage 2 or 3 ER+ breast cancer showed that the addition of a CDK4/6 inhibitor significantly lowers Ki67, suggesting that the addition of CDK4/6 inhibition can improve the efficacy of NET …”
Section: Discussionmentioning
confidence: 99%
“…Several ongoing trials are combining endocrine therapy with selective inhibitors of the PI3K/Akt/mTOR/D-cyclin-CDK4/6 pathways in the neoadjuvant setting, such as letrozole with or without the PI3K inhibitor taselisib (LORELEI) and letrozole with or without the CDK4/6 inhibitor palbociclib (PALLET) . Preliminary analysis of a phase 2 trial examining palbociclib combined with anastrozole as neoadjuvant therapy for stage 2 or 3 ER+ breast cancer showed that the addition of a CDK4/6 inhibitor significantly lowers Ki67, suggesting that the addition of CDK4/6 inhibition can improve the efficacy of NET …”
Section: Discussionmentioning
confidence: 99%
“…CH 4 is activated on the metal sites forming CH x species, which dimerize to C 2 H y . Subsequent oligomerization on the acidic sites located inside the zeolite pores yields benzene and naphthalene, as well as copious amounts of coke (19)(20)(21). Commercial prospects for this process are further hampered by the instability of zeolites at the very high reaction temperatures.…”
mentioning
confidence: 99%